Reticuloendothelial system phagocytic function in patients with Hodgkin's disease.

Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. J Clin Invest (1978) 1.45

Disordered function of mononuclear phagocytes in malignant disease. J Clin Pathol (1983) 1.33

Correlation between immune complexes and prognostic factors in Hodgkin's disease. Clin Exp Immunol (1978) 1.11

Decreased tuftsin concentrations in patients who have undergone splenectomy. Br Med J (1977) 1.05

Hypercatabolism of IgG, IgA, IgM, and albumin in the Wiskott-Aldrich syndrome. A unique disorder of serum protein metabolism. J Clin Invest (1971) 1.05

Neutrophil function in lymphoreticular malignancy. Br J Cancer (1976) 1.04

Suggested models of ecotaxopathy in lymphoreticular malignancy. A role for iron-binding proteins in the control of lymphoid cell migration. Am J Pathol (1978) 1.02

Fluorescent probes detecting the phagocytic phase of apoptosis: enzyme-substrate complexes of topoisomerase and DNA. Molecules (2011) 0.92

Immune responsiveness in Hodgkin's disease. Br J Cancer Suppl (1973) 0.81

[Sturcture and function of the mononuclear phagocytic system (MPS) in chronic rhinosinusitis. A light and electron microscopic investigation (author's transl)]. Arch Otorhinolaryngol (1976) 0.78

The control of cancer spread by the reticuloendothelial system. Ann R Coll Surg Engl (1972) 0.75

Alterations in spleen growth and sequestering function in animals receiving trypan blue. Br J Exp Pathol (1981) 0.75

Increased luminol-enhanced chemiluminescence of blood monocytes and granulocytes in Hodgkin's disease. Clin Exp Immunol (1991) 0.75

THE DEVELOPMENT OF MALIGNANT LYMPHOMA IN THE COURSE OF SJOEGREN'S SYNDROME. Am J Med (1964) 4.07

Studies on delayed hypersensitivity in Hodgkin's disease. J Clin Invest (1962) 3.20

[Phagocytosis of a fraction of heated and iodated serum by the reticuloendothelial system and subsequent behavior of its cells toward other colloids]. Ann Inst Pasteur (Paris) (1955) 3.14

PHAGOCYTOSIS OF THE ANTIGEN, A CRUCIAL STEP IN THE INDUCTION OF THE PRIMARY RESPONSE. Proc Natl Acad Sci U S A (1965) 3.05

CYTOPLASMIC INTERACTION BETWEEN MACROPHAGES AND LYMPHOCYTIC CELLS IN ANTIBODY SYNTHESIS. Science (1964) 2.77

Studies of the reticuloendothelial system (RES). I. Measurement of the phagocytic capacity of the RES in man and dog. J Clin Invest (1963) 2.67

Autoimmune disease in NZB-Bl mice. II. Autoimmunity and malignant lymphoma. Blood (1966) 2.51

Changes in the activity of the reticulo-endothelial system (RES) following the injection of parental spleen cells into F1 hybrid mice. Br J Exp Pathol (1961) 2.13

Delayed-type hypersensitivity and the immunology of Hodgkin's disease, with a parallel examination of sarcoidosis. Cancer Res (1966) 2.10

Systemic rheumatic disease and malignant lymphoma. Arch Intern Med (1963) 2.00

Hodgkin's disease and immunity. Am J Med (1956) 1.98

Activity of the reticuloendothelial system in diseases of altered immunity. J Lab Clin Med (1965) 1.93

Malignant lymphomas following allogenic disease: transition from an immunological to a neoplastic disorder. Science (1965) 1.92

In vitro transfer of macrophage RNA to lymph node cells. Nature (1963) 1.92

Anergy and skin homograft survival in Hodgkin's disease. Surg Gynecol Obstet (1958) 1.70

Summary of infectious complications occurring in patients with Hodgkin's disease. Cancer Res (1966) 1.62

Increased incidence of lymphoma after injections of mice with cells differing at weak histocompatibility loci. Science (1966) 1.56

The role and function of the reticulo-endothelial system in immunological processes. J Pharm Pharmacol (1959) 1.51

Circulating antibodies in reticuloses. Lancet (1961) 1.47

Studies of the reticuloendothelial system (RES). II. Changes in the phagocytic capacity of the RES in patients with certain infections. J Clin Invest (1963) 1.41

MECHANISMS OF ENDOTOXIN TOLERANCE. II. RELATIONSHIP BETWEEN ENDOTOXIN TOLERANCE AND RETICULOENDOTHELIAL SYSTEM PHAGOCYTIC ACTIVITY IN MAN. J Exp Med (1964) 1.30

STUDIES OF THE RETICULOENDOTHELIAL SYSTEM (RES). 3. BLOCKADE OF THE RES IN MAN. J Clin Invest (1964) 1.29

Reticular tumours in mice subjected to prolonged antigenic stimulation. Br J Cancer (1961) 1.25

Exploration of the phagocytic function of the reticuloendothelial system with heat denatured human serum albumin labeled with I131 and application to the measurement of liver blood flow, in normal man and in some pathologic conditions. J Lab Clin Med (1958) 1.15

LYMPHOCYTOPENIA IN HODGKIN'S DISEASE. Blood (1965) 1.01

Susceptibility of mice to pneumococcal infection after modification of the reticuloendothelial system with simple lipids. J Pathol Bacteriol (1962) 0.98

Reticuloendothelial phagocytic function in patients with leukemia, lymphoma and multiple myeloma. Blood (1965) 0.97

Se methionine as a diagnostic agent in malignant lymphoma. J Nucl Med (1965) 0.93

ENHANCED RETICULOENDOTHELIAL PHAGOCYTIC ACTIVITY IN MYELOPROLIFERATIVE DISEASES. J Reticuloendothel Soc (1965) 0.89

Antibody response in hematologic patients. Proc Soc Exp Biol Med (1961) 0.84

[Measurement of the phagocytic activity of the reticulo-endothelial system in clinical practice by denatured human albumin labelled with I-131. Considerations on the measurement of hepatic circulation in cirrhosis]. Schweiz Med Wochenschr (1960) 0.78

Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore) (1975) 9.01

Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A (1984) 8.84

Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med (1983) 8.26

Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med (1988) 7.96

Cellular immunity in vitro. I. Immunologically mediated enhancement of macrophage bactericidal capacity. J Exp Med (1971) 4.94

Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) (1973) 4.89

Enhancement of macrophage bactericidal capacity by antigenically stimulated immune lymphocytes. Cell Immunol (1972) 3.56

The role of interleukin-1 in disease. N Engl J Med (1993) 3.45

Nonspecificity of the limulus amebocyte lysate test: positive reactions with polynucleotides and proteins. J Infect Dis (1973) 3.40

Impaired delayed hypersensitivity in patients with lepromatous leprosy. Lancet (1966) 3.26

Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A (1977) 3.15

Staphylococcus aureus. The persistent pathogen (first of two parts). N Engl J Med (1984) 3.15

Demonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med (1974) 2.98

The cardiovascular manifestations of the hypereosinophilic syndrome. Prospective study of 26 patients, with review of the literature. Am J Med (1979) 2.86

The Chediak-Higashi syndrome: studies in four patients and a review of the literature. Medicine (Baltimore) (1972) 2.74

Molecular basis of fever in humans. Am J Med (1982) 2.69

Serious infections from Bacillus sp. JAMA (1979) 2.67

Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science (1991) 2.37

Editorial: Gram-negative-rod bacteremia. N Engl J Med (1974) 2.36

Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med (1974) 2.35

Induction of human interleukin-1 by a product of Staphylococcus aureus associated with toxic shock syndrome. J Clin Invest (1984) 2.33

The ocular manifestations of Wegener's granulomatosis. Fifteen years experience and review of the literature. Am J Med (1977) 2.26

Staphylococcus aureus. The persistent pathogen (second of two parts). N Engl J Med (1984) 2.23

Studies on the origin of human leukocytic pyrogen. J Exp Med (1970) 2.22

A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci U S A (1988) 2.22

In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus. Antimicrob Agents Chemother (1978) 2.21

Juvenile rheumatoid arthritis presenting in the adult as fever of unknown origin. Medicine (Baltimore) (1973) 2.21

Teichoic acid serologic diagnosis of staphylococcal endocarditis. Use of gel diffusion and counterimmunoelectrophoretic methods. Ann Intern Med (1975) 2.15

Wegener's granulomatosis. Ann Intern Med (1974) 2.13

Microbiologic study of street heroin and injection paraphernalia. J Infect Dis (1974) 2.10

Granulocyte function in the Chediak-Higashi syndrome of mice. Blood (1974) 2.04

Impact of encephalopathy on mortality in the sepsis syndrome. The Veterans Administration Systemic Sepsis Cooperative Study Group. Crit Care Med (1990) 2.04

The present medical database needs reorganization. It's time for a change! Arch Intern Med (1990) 2.02

Malaria: host-defense mechanisms and complications. Ann Intern Med (1970) 2.00

Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery (1988) 1.98

Epidemiology and clinical significance of blood cultures positive for coagulase-negative staphylococcus. Infect Control (1985) 1.95

New concepts on the pathogenesis of fever. Rev Infect Dis (1988) 1.94

Changes in human serum amyloid A and C-reactive protein after etiocholanolone-induced inflammation. J Clin Invest (1978) 1.90

Staphylococcus aureus bacteremia: relationship between formation of antibodies to teichoic acid and development of metastatic abscesses. J Infect Dis (1978) 1.88

Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N Engl J Med (1979) 1.87

Monoclonal antibodies and the treatment of gram-negative bacteremia and shock. N Engl J Med (1991) 1.86

Factors affecting the quantitative production and assay of human leukocytic pyrogen. J Lab Clin Med (1970) 1.86

The production of antibody against human leukocytic pyrogen. J Clin Invest (1977) 1.84

Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years. N Engl J Med (1982) 1.83

Staphylococcal endocarditis in drug users. Clinical and microbiologic aspects. Arch Intern Med (1975) 1.83

Further developments of Limulus Amebocyte Lysate test. Bull Parenter Drug Assoc (1973) 1.81

Characterization and significance of abnormal leukocyte granules in the beige mouse: a possible homologue for Chediak-Higashi Aleutian trait. J Lab Clin Med (1969) 1.80

Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med (1974) 1.80

Angiosarcoma of the liver following vinyl chloride exposure. JAMA (1974) 1.77

A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol (1995) 1.76

The Chediak-Higashi syndrome: studies of host defenses. Ann Intern Med (1972) 1.76

In vitro production of IL 1 beta, IL 1 alpha, TNF and IL2 in healthy subjects: distribution, effect of cyclooxygenase inhibition and evidence of independent gene regulation. Eur J Immunol (1989) 1.73

Factitious fever and self-induced infection: a report of 32 cases and review of the literature. Ann Intern Med (1979) 1.73

Sleep-promoting effects of endogenous pyrogen (interleukin-1). Am J Physiol (1984) 1.70

Increased incidence of Staphylococcus aureus bacteremia in hospitalized patients with acquired immunodeficiency syndrome. Clin Infect Dis (2001) 1.70

Effect of cyclophosphamide upon the immune response in Wegener's granulomatosis. N Engl J Med (1971) 1.70

Leukocytic function in hypogammaglobulinemia. J Clin Invest (1970) 1.65

Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine (1992) 1.63

Bladder toxicity with chronic oral cyclophosphamide therapy in nonmalignant disease. Arthritis Rheum (1973) 1.61

The pyrogenicity of the synthetic adjuvant muramyl dipeptide and two structural analogues. J Infect Dis (1978) 1.59

Therapy of the hypereosinophilic syndrome. Ann Intern Med (1978) 1.58

Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep (1970) 1.55

Anticytokine strategies in the treatment of the systemic inflammatory response syndrome. JAMA (1993) 1.54

Hepatocellular carcinoma. Diagnostic and prognostic features in North American patients. Cancer (1984) 1.54

Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis. Ann Intern Med (1975) 1.53

Production of interleukin-1-receptor antagonist during experimental endotoxaemia. Lancet (1991) 1.53

Defective granulocyte regulation in the Chediak-Higashi syndrome. N Engl J Med (1968) 1.51

Methotrexate treatment of idiopathic granulomatous hepatitis. Ann Intern Med (1995) 1.50

Teichoic acid antibodies in the diagnosis of serious infections with Staphylococcus aureus. Ann Intern Med (1976) 1.49

Intravenous endotoxin suppresses the cytokine response of peripheral blood mononuclear cells of healthy humans. J Immunol (1993) 1.45

Antagonism of toxigenic Clostridium difficile by nontoxigenic C. difficile. J Infect Dis (1983) 1.45

Biology of endotoxin. Annu Rev Med (1976) 1.44

Inhibition of cyclo-oxygenase attenuates the metabolic response to endotoxin in humans. Arch Surg (1988) 1.44

Cleavage of human interleukin 1: isolation of a peptide fragment from plasma of febrile humans and activated monocytes. J Immunol (1984) 1.44

Population dynamics of ingested Clostridium difficile in the gastrointestinal tract of the Syrian hamster. J Infect Dis (1985) 1.44

Pathogenesis of fever in man. N Engl J Med (1978) 1.43

Alternate-day prednisone therapy. Evaluation of delayed hypersensitivity responses, control of disease and steroid side effects. N Engl J Med (1969) 1.42

Inhibition of biologic activity of poly I: poly C by human plasma. Proc Soc Exp Biol Med (1970) 1.42

Effect of induced fever on serum iron and ferritin concentrations in man. Blood (1977) 1.41

Rectal abscesses in cancer patients. Lancet (1972) 1.40

The role of iron in nonspecific resistance to infection induced by endotoxin. J Immunol (1974) 1.40

Septicemia due to Mycoplasma hominis type 1. N Engl J Med (1965) 1.40

Immunologic reactivity in patients with leprosy. Ann Intern Med (1969) 1.39

Bactericidal and metabolic properties of human eosinophils. Blood (1972) 1.38

Lack of clinical usefulness of the limulus test in the diagnosis of endotoxemia. N Engl J Med (1975) 1.36

Effect of prophylactic colchicine therapy on leukocyte function in patients with familial Mediterranean fever. Arthritis Rheum (1976) 1.36

Effect of indomethacin on increased resistance to bacterial infection and on febrile responses induced by muramyl dipeptide. J Infect Dis (1980) 1.35

Impaired in vitro lymphocyte transformation in patients with ataxia-telangiectasis. Br Med J (1966) 1.34

Gnotobiotic models for study of the microbial ecology of Clostridium difficile and Escherichia coli. J Infect Dis (1986) 1.34

Detection of endotoxin in cerebrospinal and joint fluids by limulus assay. Arch Intern Med (1977) 1.33

Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance. Clin Pharmacol Ther (1975) 1.32

Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest (1975) 1.32

Endotoxin-induced modification of Plasmodium berghei infection in mice. J Immunol (1969) 1.31